BCL6 Is Regulated by the MAPK/ELK1 Axis and Promotes KRAS-Driven Lung Cancer

Investigators identified B cell lymphoma 6 (BCL6) as a lynchpin in KRAS-driven lung cancer, revealing a crucial role of BCL6 in promoting KRAS-addicted lung cancer and suggested BCL6 as a therapeutic target for the treatment of this intractable disease.